The power of r – pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?

References

• Maynard A, McDaid D. Evaluating health interventions: exploiting the potential. Health Policy 2003;63(2):215-26
   Google Scholar
• Dubois RW, Chawla AJ, Neslusan CA, et al. Explaining drug spending trends: does perception match reality? Health Aff 2000;19(2):231-9
   PubMedGoogle Scholar
• Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998;80:108-16
   Web of Science ®Google Scholar
• Abboud C, Berman E, Cohen A, et al. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42
   PubMed Web of Science ®Google Scholar
• American Sociological Association. Pharmaceuticals: a market for producing ‘lemons’ and serious harm, analysis finds. ScienceDaily; 2010.
   Google Scholar
• Meyer F. Outlook and challenges for the future A French perspective. HAS; 2011
   Google Scholar
• Gridchyna I, Aulois-Griot M, Maurain C, Bégaud B. How innovative are pharmaceutical innovations? The case of medicines financed through add-on payments outside of the French DRG-based hospital payment system. Health Policy 2012;104(1):69-75
   PubMed Web of Science ®Google Scholar
• Walker A, Booth C, Brown A, Paterson K. How much good do new medicines do? Basic Clin Pharm Toxicol 2009;105(Suppl 1):29
   Google Scholar
• Rhee J. The influence of the pharmaceutical industry on healthcare practitioners prescribing habits. Internet J Acad Phys Assist 2008;7(1):4
   Google Scholar
• Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. Int J Health Care Finance Econ 2005;5:47-73
   PubMedGoogle Scholar
• Scherer FM. Pricing, profits, and technological progress in the pharmaceutical industry. J Econ Perspect 1993;7(3):97-115
   Web of Science ®Google Scholar
• Kanavos P, Vandegrift M. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 1997;41:241-26
   Google Scholar
• Vogler S, Zimmermann N. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev 2011;4(2):69-79
   PubMedGoogle Scholar
• OECD (2009) OECD stat (database). HealthCare resources: Pharmacists. Available from: http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT [Last assessed February 2014]
   Google Scholar
• OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database. [Last assessed February 2014]
   Google Scholar
• OECD. Health at a Glance; 2012
   Google Scholar
• Kannavos P, Seeley L, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. London School of Economics; 2009
   Google Scholar
• Dylst P, Vulto A, Simoens S. Tendering for outpatients prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy 2011;101:146-52
   PubMed Web of Science ®Google Scholar
• Zuidberg C. The pharmaceutical system of the Netherlands. PPRI; Vienna, The Netherlands: 2010
   Google Scholar
• Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solution for a sustainable drug market? Appl Health Econ Health Policy 2013;11:437-43
   PubMedGoogle Scholar
• Penny Wise, Pound Foolish? Ronald Beger Strategic Consultant, The Netherlands
   Google Scholar
• Shrank WH, Ettner SL, Glassman P, Asch SM. A bitter pill: formulary variability and the challenge to prescribing physicians. J Am Board Fam Pract 2004;17:401-7
   Google Scholar
• Trice S, Devine J, Mistry H, et al. Formulary management in the department of defence. J Manag Care Pharm 2009;15:133-46
   Google Scholar
• Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684-9
   Web of Science ®Google Scholar
• Report 2 of the Council on Scientific Affairs (A-04) Impact of Drug Formularies and Therapeutic Interchange on Health Outcomes. Available from: www.ama-assn.org/resources/doc/csaph/a04csa2-fulltext.pdf
   Google Scholar
• Gustafsson LL, Wettermark B, Godman B. The ‘Wise List’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33
   PubMed Web of Science ®Google Scholar
• Has Sante Health Technology Assesment of etoricoxib. Transparency Committee Opinion 29 April 2009. Available from: www.has-sante.fr/portail/upload/docs/application/pdf/2011-05/arcoxia_30_et_60_mg_ct_5948.pdf [Last assessed August 2013]
   Google Scholar
• Common practices in formulary management systems. A report prepared by the Acaddemy of American Care Pharmacy. Available from: http://amcp.org/WorkArea/DownloadAsset.aspx?id=9274
   Google Scholar
• Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21(2):89-103
   PubMed Web of Science ®Google Scholar
• 23.06.010.01.646, 26 March 2012, Issue Raised by member of Parliament Hadjiyiannis Kyriakos. Available from: www.parliament.cy/parliamentgr/008_02/chronological/008_02_IA.htm [Last assessed July 2013]
   Google Scholar
• Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – an overview. GaBI 2012;1(2):93-100
   Google Scholar
• Köberlein J, Gottschall M, Czarnecki K. General practitioners' views on polypharmacy and its consequences for patient health care. BMC Family Practice 2013;14:119
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacy Administration. Polypharmacy in Public Sector. MOH; Cyprus: 2011
   Google Scholar
• Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to recude reimbursmenent costs. Expert Rev Pharmacoecon Outcomes Res 2011;11:121-9
   PubMed Web of Science ®Google Scholar
• Villalba Van Dijk L, De Vries H, Bell DS. Electronic Prescribing in the United Kingdom and in the Netherlands. (Prepared by RAND Europe under Contract No. RD-141-AHRQ.) AHRQ Publication No. 11-0044-EF. Agency for Healthcare Research and Quality; Rockville, MD, USA: 2011
   Google Scholar
• Wang CJ, Huang AT. Integrating technology into health care: what will it take? JAMA 2012;307(6):569-70
   PubMed Web of Science ®Google Scholar
• Garattin L, Cornago D, Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 2007;82:330-9
   Google Scholar
• OECD Health Data 2010; Eurostat Statistics Database. Average annual real growth in pharmaceuticals expenditure compared to total health expenditure. 1998-2008
   Google Scholar
• Petrou P, Talias M. A framework for applying health technology assessment in Cyprus: thoughts, success stories, and recommendations. Value Health Regional Issues 2013;2:273-8
   PubMedGoogle Scholar
• Gerdtham U-G, Johannesson M, Gunnarsson B. The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics 1998;13(1 Pt 2):127-34
   Google Scholar
• Gerdtham UG, Johannesson M, Jonsson B. Drug expenditure and new drug introductions: the Swedish experience. Pharmacoeconomics 1993;4(3):215-25
   Google Scholar
• Lambrelli D, O'Donnell O. The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece. Health Policy 2011;101:162-71
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Available from: www.whocc.no/atc_ddd_index/ [Last assessed September 2013]
   Google Scholar
• German Association for Pharmaceutical Industry (BPI e.V.) Pharma Data. 2011; Available from: www.bpi.de/fileadmin/media/bpi/Downloads/Internet/Publikationen/Pharma-Daten/Pharmadaten%202011%20EN.pdf [Last assessed March 2013]
   Google Scholar
• Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011;365:385-8
   PubMed Web of Science ®Google Scholar
• DIMDI. ATC-classification with defined daily doses. Available from: www.dimdi.de/static/en/klassi/atcddd/index.htm [Last assessed March 2013]
   Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101(15):1044-8
   PubMedGoogle Scholar
• Culyer AJ, Lomas J. Deliberative processes and evidence-informed decision making in healthcare: do they work and how might we know? Evid Policy 2006;2:357-71
   Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:707-22
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12:125-30
   PubMed Web of Science ®Google Scholar
• Woerkom MV, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in the Netherlands; influence and future implications. J Comp Eff Res 2012;1:527-38
   PubMed Web of Science ®Google Scholar
• Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-27
   PubMed Web of Science ®Google Scholar
• European CDC. Summary of latest data on antibiotic consumption in Europe. Available from: www.ecdc.europa.eu/en/eaad/documents/eaad-2011-summary-antimicrobial-consumption-data.pdf
   Google Scholar
• Godman B, Persson M, Miranda J, et al. Can authorities take advantage of the availability of generic atypical antipsychotic drugs:/Findings from Sweden and potential implications. J Pharm Health Serv Res 2013;4:139-50
   Google Scholar
• Ebbers HC, Mantel-Teeuwisse AK, Moors EH, et al. Todays Challenges in Pharmacovigilance: what can we Learn from Epoetins? Drug Saf 2011;34(4):273-87
   PubMed Web of Science ®Google Scholar
• NICE. 2008.Appraising end of life medicines. Available from: www.nice.org.uk/media/26E/43/Endoflifemedicines.pdf
   Google Scholar
• Blackett T, Robins R. Brand Medicine: the role of branding in the pharmaceutical industry. Tom Blackett and Rebecca Robins, NY, USA; 2001
   Google Scholar
• Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res 2010;10:128
   PubMed Web of Science ®Google Scholar
• Schiff GD, Galanter WL, Duhig J, et al. A prescription for improving drug formulary decision making. Plos Med 2012;9(5):1-7
   PubMed Web of Science ®Google Scholar
• PHIS. Available from: https://phis.goeg.at/index.aspx?_nav0021 [Last assessed January 2014]
   Google Scholar
• Maynard A, Bloor K. Will financial incentives and penalties improve hospital care? BMJ 2010;340:297-8
   Google Scholar
• Making the NHS more efficient and less bureaucratic. Available from: www.dh.gov.uk/health/category/policy-areas/nhs/quality/qipp/medicines-procurement/ [Last assessed November 2013]
   Google Scholar
• MOH. Pharmaceutical sale 2005-2011. MOH, Nicosia, Cyprus; 2012
   Google Scholar
• Martirosyan L, Arah OA, Haaijer-Ruskamp FM, et al. Methods to identify the target population: implications for prescribing quality indicators. BMC Health Serv Res 2010;10:137
   PubMed Web of Science ®Google Scholar
• Framework guidance for GMS contract 2013. 2013/14 general medical services (GMS) contract quality and outcomes framework (QOF). The NHS Confederation (Employers) Company Ltd. Available from: www.nhsemployers.org [Last assessed February 2014]
   Google Scholar
• O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007;4:CD000409
   PubMed Web of Science ®Google Scholar
• Avorn J. Transforming trials results into practice care. Arch Intern Med 2010;170(10):858-60
   Google Scholar
• Petersen LA, Simpson K, Pietz K, et al. Effects of individual physician-level and practice-level financial incentives on hypertension care: a randomized trial. JAMA 2013;310(10):1042-50
   PubMed Web of Science ®Google Scholar
• Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ 2011;342:d108
   PubMed Web of Science ®Google Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self –assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009;17:179-89
   PubMedGoogle Scholar
• Benjamin A. Audit: how to do it in practice. BMJ 2008;336:1241-5
   PubMed Web of Science ®Google Scholar
• Kanavos P. Overview of pharmaceutical pricing and reimbursement regulation in Europe. LSE Health and Social Care; London, UK: 2001
   Google Scholar
• Pauly M, Blavin F. Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignorance. J Health Econ 2008;27:1407-17
   Web of Science ®Google Scholar
• Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;5(1):e1
   PubMed Web of Science ®Google Scholar
• OECD (2010) Health at a Glance: Europe 2010. OECD Publishing. DOI:10.1787/health_glance-2010-en. Available from: www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/health-at-a-glance-europe-2010_health_glance-2010-en#page111 [Last assessed February 2014]
   Google Scholar
• Addis A, Magrini N. New approaches to analyzing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. Pharmacoepidemiol Drug Saf 2002;11:721-6
   PubMed Web of Science ®Google Scholar